Last updated: July 7, 2026
Executive summary
ADAPT PHARMA OPERATIONS LIMITED sued TEVA PHARMACEUTICALS USA, INC. in the District of New Jersey over an FDA Abbreviated New Drug Application likely framed as an Orange Book Paragraph IV dispute. The docket number is 2:16-cv-07721-JLL-JAD, with Judge Jose L. Linares (JLL) and Judge Joel A. dockets Rosen (JAD). The public record available from this chat does not include case disposition, asserted patent numbers, claim construction outcomes, settlement terms, or final judgment. Without those inputs, a complete and accurate litigation summary and analysis cannot be produced.
What patents were asserted in ADAPT PHARMA OPERATIONS LIMITED v. TEVA PHARMACEUTICALS USA (2:16-cv-07721-JLL-JAD)?
A litigation summary depends on the asserted Orange Book-listed patents (numbers, expiration dates, and remaining regulatory exclusivities) and the exact allegations in the complaint and any amended pleadings. The case caption provided does not include the asserted patents or the drug/product at issue, and no patent list or complaint text is available in the provided information.
Which Orange Book patents are typically listed in these Paragraph IV filings?
In Hatch-Waxman litigation, the complaint typically asserts one or more Orange Book patents tied to:
- Drug substance
- Drug product formulation
- Manufacturing method
- Method of use (if applicable)
- Packaging, dosing regimen, or other specific claims
No Orange Book entry set or patent numbers are present here, so the asserted estate cannot be reconstructed.
What was TEVA’s FDA ANDA filing and Paragraph IV notice for in this case?
A correct analysis requires at least:
- The reference listed drug (RLD)
- The ANDA number
- The notified patents (and each Paragraph IV allegation: invalidity and/or non-infringement)
- The FDA approval status (tentative approval vs final approval)
- Any design-around (formulation or method changes) cited in TEVA’s defenses
The provided docket identifier does not include these details.
What regulatory pathway drove the timing and exclusivity window?
Hatch-Waxman timing is determined by:
- RLD exclusivities (3-year new clinical, 5-year new chemical entity, pediatric exclusivity where applicable)
- Patent expiration dates for the asserted patents
- Whether any pediatric extension applied
- Potential 30-month stay (if triggered by a timely suit)
No exclusivity and no FDA pathway details are supplied in the input.
When did ADAPT PHARMA sue TEVA, and what was the procedural timeline?
A procedural timeline requires docket events such as:
- Complaint filing date
- Service and answer date
- Claim construction schedule
- Motions to dismiss, summary judgment, preliminary injunction
- Trial date setting or status conference dates
- Settlement or dismissal order dates
The input provides only the case number and parties, not the docket dates or orders.
Was there a preliminary injunction attempt or 30-month stay fight?
In Paragraph IV cases, common inflection points include:
- Preliminary injunction motions (to block FDA approval)
- Discovery orders and expert report deadlines
- Staying FDA approval timelines during litigation
No motion filings or hearing outcomes are included in the provided data.
How did the court rule on infringement and invalidity in this case?
A litigation analysis must address:
- Claim construction rulings
- Infringement findings (literal and doctrine of equivalents)
- Invalidity grounds (35 USC §101, §102, §103, §112, and obviousness-type double patenting where applicable)
- Final judgment posture (dismissal, summary judgment, consent judgment)
No rulings, claim construction outcomes, or final disposition are available here.
What settlement or dismissal terms resolved ADAPT vs TEVA (2:16-cv-07721-JLL-JAD)?
Settlement and dismissal terms drive:
- Launch dates
- Carve-outs (design-around acceptance)
- License scope
- Payment and confidentiality structure
- Stipulated dismissal with or without prejudice
- Entry into a consent judgment that constrains generic launch
No settlement or dismissal order details are included in the input.
What is the likely impact on generic entry risk for TEVA?
Risk assessment depends on:
- Whether TEVA received FDA approval during litigation
- Whether the asserted patents were invalidated or found not infringed
- Whether there was a stipulated launch date or ongoing injunction
- Whether any remaining unasserted patents could still block launch
Because the asserted patents, rulings, and any consent timetable are missing, a defensible generic entry risk statement cannot be completed.
How strong is the ADAPT patent estate in this dispute versus TEVA’s defenses?
Strength scoring requires:
- The number of asserted patents
- Their claim breadth
- The novelty of the formulation or method claims
- Prior art landscape and obviousness posture
- Litigation history and earlier validity determinations
- Whether TEVA successfully attacked enablement, written description, or indefiniteness
None of these elements are present.
How do formulation and method-of-use claims usually behave in litigation like this?
In many Hatch-Waxman disputes:
- Formulation claims can be vulnerable to obviousness if art shows similar compositions and routine optimization.
- Method-of-use claims can hinge on induced infringement proof and label-based evidence.
- Manufacturing method claims depend on process documentation and comparators.
This is general doctrine and cannot be tied to this specific case without the pleadings.
What is the Orange Book status of the RLD in this case, and which patents remain in force?
Orange Book status requires:
- RLD and ANDA linkages
- Listed patent numbers and expiration dates
- Patent exclusivity expiration and any pediatric exclusivity
- Any non-listed patent litigation posture where relevant
No RLD, Orange Book listing, or patent list is provided.
Key takeaways
- The provided input identifies the parties and the docket number for ADAPT PHARMA OPERATIONS LIMITED v. TEVA PHARMACEUTICALS USA, INC. (2:16-cv-07721-JLL-JAD).
- A complete litigation summary and analysis requires asserted patent numbers, procedural dates, claim construction or merits rulings, and final disposition or settlement terms.
- Those elements are not contained in the input, so an accurate summary and analysis cannot be produced from the available information.
FAQs
- Does 2:16-cv-07721-JLL-JAD correspond to a Paragraph IV ANDA challenge?
- Which patents were listed on the Orange Book for the RLD involved in ADAPT v. TEVA?
- Was there a consent judgment or stipulated dismissal tied to a generic launch date?
- Did the court issue claim construction rulings that narrowed or broadened key claims?
- Did FDA approval (tentative or final) occur during or after the litigation stay period?
References
- United States District Court for the District of New Jersey. Case docket: ADAPT PHARMA OPERATIONS LIMITED v. TEVA PHARMACEUTICALS USA, INC., No. 2:16-cv-07721-JLL-JAD.
